Loading…
HLB Group subsidiaries will acquire 30 billion won ($22.8 million) worth of equity in PSMC, a lead frame manufacturer, making HLB the largest shareholder with a 28.25% stake. PSMC will change its name to HLB innovation and add biopharmaceutical lines to develop CAR-T treatments.